Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2019 1
2020 5
2021 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A, Tanda ET, Croce E, Catalano F, Ceppi M, Bruzzone M, Cecchi F, Arecco L, Fraguglia M, Pronzato P, Genova C, Del Mastro L, Lambertini M, Spagnolo F. Boutros A, et al. Among authors: cecchi f. Eur J Cancer. 2023 Jul;188:64-79. doi: 10.1016/j.ejca.2023.04.010. Epub 2023 Apr 24. Eur J Cancer. 2023. PMID: 37196485 Free article. Review.
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
Tanda ET, d'Amato AL, Rossi G, Croce E, Boutros A, Cecchi F, Spagnolo F, Queirolo P. Tanda ET, et al. Among authors: cecchi f. Front Oncol. 2021 Sep 23;11:739006. doi: 10.3389/fonc.2021.739006. eCollection 2021. Front Oncol. 2021. PMID: 34631574 Free PMC article. Review.
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma.
Boutros A, Cecchi F, Tanda ET, Croce E, Gili R, Arecco L, Spagnolo F, Queirolo P. Boutros A, et al. Among authors: cecchi f. Front Oncol. 2021 Aug 26;11:733917. doi: 10.3389/fonc.2021.733917. eCollection 2021. Front Oncol. 2021. PMID: 34513710 Free PMC article. Review.
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
Spagnolo F, Croce E, Boutros A, Tanda E, Cecchi F, Mascherini M, Solari N, Cafiero F, Queirolo P. Spagnolo F, et al. Among authors: cecchi f. Expert Rev Anticancer Ther. 2020 May;20(5):403-413. doi: 10.1080/14737140.2020.1760847. Epub 2020 May 3. Expert Rev Anticancer Ther. 2020. PMID: 32326767 Review.
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fargnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A. Nigro O, et al. Among authors: cecchi f. Eur J Cancer. 2020 Jul;134:19-28. doi: 10.1016/j.ejca.2020.04.025. Epub 2020 May 23. Eur J Cancer. 2020. PMID: 32454395
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab.
Pistillo MP, Carosio R, Grillo F, Fontana V, Mastracci L, Morabito A, Banelli B, Tanda E, Cecchi F, Dozin B, Gualco M, Salvi S, Spagnolo F, Poggi A, Queirolo P. Pistillo MP, et al. Among authors: cecchi f. Clin Immunol. 2020 Jun;215:108428. doi: 10.1016/j.clim.2020.108428. Epub 2020 Apr 25. Clin Immunol. 2020. PMID: 32344017
14 results